---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-26-000073"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2026-07-29T10:10:24+00:00"
generated_at: "2026-07-29T10:15:23.669651+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biogen Q2 revenue $2.7B (+3% YoY); GAAP EPS $0.66, Non-GAAP $3.60; Growth Portfolio up 24% to $1.06B

## Summary
- Total revenue $2.7B (+3% YoY); GAAP diluted EPS $0.66 (down 85%), Non-GAAP diluted EPS $3.60 (down 34%).
- Growth Portfolio revenue $1.06B (+24% YoY); SPINRAZA $402M (+2%), LEQEMBI in-market $184M (+15%), SKYCLARYS $168M (+29%).
- Apellis acquisition closed May 14; SYFOVRE $162M (Biogen $97M), EMPAVELI $46M (Biogen $30M); $0.85 dilution to Non-GAAP EPS in 2026, accretive 2027.
- Pipeline: litifilimab SLE data by end-2026; diranersen proof-of-concept in Alzheimer's; pending RayThera acquisition.
- Full year 2026 guidance updated reflecting stronger underlying business outlook adjusted for transactions and milestones.

## SEC filing metadata
- accession: 0000875045-26-000073
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2026-07-29T10:10:24+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/0000875045-26-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/biib-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-26-000073
- JSON: https://secwatch.observer/filing/0000875045-26-000073.json
- Plain text: https://secwatch.observer/filing/0000875045-26-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.